Abstract
Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 59-68 |
| Number of pages | 10 |
| Journal | Future Oncology |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2014 |
Fingerprint
Keywords
- leiomyosarcoma
- liposarcoma
- sarcoma
- second-line treatment
- STS
- trabectedin
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)
Cite this
Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. / Blay, Jean Yves; Casali, Paolo; Nieto, Antonio; Tanović, Adnan; Cesne, Axel Le.
In: Future Oncology, Vol. 10, No. 1, 01.01.2014, p. 59-68.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma
AU - Blay, Jean Yves
AU - Casali, Paolo
AU - Nieto, Antonio
AU - Tanović, Adnan
AU - Cesne, Axel Le
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
AB - Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
KW - leiomyosarcoma
KW - liposarcoma
KW - sarcoma
KW - second-line treatment
KW - STS
KW - trabectedin
UR - http://www.scopus.com/inward/record.url?scp=84904812022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904812022&partnerID=8YFLogxK
U2 - 10.2217/fon.13.163
DO - 10.2217/fon.13.163
M3 - Article
C2 - 23987833
AN - SCOPUS:84904812022
VL - 10
SP - 59
EP - 68
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 1
ER -